RET and medullary thyroid gland carcinoma: Mutation-selective kinase inhibitor such as RET-inhibitor selpercatinib is FDA-approved for the treatment of metastatic RET-mutant MTC or RET-fusion mutant differentiated thyroid cancers with phase II clinical trial showing an overall response rate of 70%.